Core Viewpoint - The stock of Boan Biotechnology (06955) fell over 8% following the release of its interim results, indicating market concerns regarding its profitability despite revenue growth [1] Financial Performance - For the first half of the year, Boan Biotechnology reported revenue of RMB 393 million, an increase of 8.4% year-on-year [1] - Gross profit remained stable at RMB 283 million, showing no significant change compared to the previous year [1] - The profit attributable to the parent company was RMB 20.514 million, a decrease of 66.7% year-on-year [1] Product Sales - The increase in revenue was primarily driven by the sales of products (Boan's You Nuo, Boan's You Bei, and Bo Luo Jia), which grew by 15.9% to RMB 385.3 million for the six months ending June 30, 2024 [1] Regulatory Approval - On August 9, Boan Biotechnology announced that its self-developed product, Boan You Ping (Dulaglutide injection), received approval from the National Medical Products Administration for market launch [1] - This product is the world's first and currently the only approved biosimilar to Trulicity, with no other domestic Dulaglutide injections having entered the market approval application stage [1] - The commercialization of Boan You Ping in mainland China will be conducted in collaboration with Shanghai Pharmaceuticals Holding Co., Ltd. [1]